Choongwae Pharma Co.'s Corporate bonds Upswing ratings of BBB-

Published: 2001-04-19 06:56:00

Updated: 2001-04-19 06:56:00

Korea Management Consulting & Credit Rating Corporation(KMCC) have adjusted upward from credit ratings of BB+ to investment rating BBB- Choongwae Pharma Co.'s Corporate bonds on April 11.

KMCC said, " As Choongwae Pharma Co.'s NCF is on a improving trend with market positions of treatment fie...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK